MedPath

German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)

Recruiting
Conditions
BCR-ABL1-Negative Myeloid Neoplasms
Registration Number
NCT03125707
Lead Sponsor
University of Ulm
Brief Summary

To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers

To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases)

To perform morphologic and genetic analyses

To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables

To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)

To assess quality of life

Detailed Description

To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers

To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases)

To perform morphologic and genetic analyses

To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables

To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)

To assess quality of life

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
2172
Inclusion Criteria

Both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry:

  • Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria
  • Age ≥ 18 years. There is no upper age limit.
  • Signed written informed consent.
Exclusion Criteria
  • Severe neurological or psychiatric disorder interfering with ability to give an informed consent
  • No consent for registration, storage and handling of the personal data

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival25 years

Survival over the whole study duration

Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.25 years

Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.

Treatment decision25 years

Treatment decision (watch and wait, standard, investigational)

Response25 years

Response of treatment

Duration of response25 years

Duration of response over the whole study duration

Progression-free-survival25 years

Survival without any progression

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Klinikum Augsburg

🇩🇪

Augsburg, Germany

Hämatologische Onkologie Praxis Augsburg

🇩🇪

Augsburg, Germany

Klinikum Mittelbaden

🇩🇪

Baden-Baden, Germany

Helios Klinikum, Bad Saarow

🇩🇪

Bad Saarow, Germany

Donauwörth, Onko-Medeor

🇩🇪

Donauwörth, Germany

MVZ Klinikum Coburg

🇩🇪

Coburg, Germany

Onkologie, BAG, Dresden

🇩🇪

Dresden, Germany

Onkologie Erding

🇩🇪

Erding, Germany

Onkologische Praxis, Heidelberg

🇩🇪

Heidelberg, Germany

Alb Fils Kliniken Göppingen

🇩🇪

Göppingen, Germany

Marienhospital Bochum-Herne

🇩🇪

Herne, Germany

Universitätsklinikum Greifswald

🇩🇪

Greifswald, Germany

Universitätsklinikum Freiburg

🇩🇪

Freiburg, Germany

Klinikum Kempten-Oberallgäu gGmbH

🇩🇪

Kempten, Germany

Onkologische Schwerpunktpraxis, Heilbronn

🇩🇪

Heilbronn, Germany

Landshut VK&K Studien GbR

🇩🇪

Landshut, Germany

Universitätsklinikum Jena

🇩🇪

Jena, Germany

Universitätsklinikum Leipzig

🇩🇪

Leipzig, Germany

Universitätsklinikum Magdeburg

🇩🇪

Magdeburg, Germany

Universitätsklinikum Mannheim

🇩🇪

Mannheim, Germany

Mühlenkreiskliniken Minden

🇩🇪

Minden, Germany

Leer, Studienzentrum Unter Ems

🇩🇪

Leer, Germany

Mannheim, Onkologiepraxis

🇩🇪

Mannheim, Germany

Memmingen, Onkologiepraxis

🇩🇪

Memmingen, Germany

Diakonie-Klinikum Stuttgart

🇩🇪

Stuttgart, Germany

Stuttgart, MVZ am RBK

🇩🇪

Stuttgart, Germany

Stauferklinikum Schwäbisch Gmünd

🇩🇪

Mutlangen, Germany

Universitätsklinikum Ulm

🇩🇪

Ulm, Germany

Rems-Murr-Kliniken Winnenden

🇩🇪

Winnenden, Germany

Würzburg / Kitzingen, Gemeinschaftspraxis Dr. Schlag

🇩🇪

Würzburg, Germany

© Copyright 2025. All Rights Reserved by MedPath